Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

87 results about "Premalignant lesion" patented technology

[edit on Wikidata] A precancerous condition or premalignant condition, sometimes called a potentially precancerous condition or potentially premalignant condition, is a term used to describe certain conditions or lesions involving abnormal cells which are associated with an increased risk of developing into cancer.

Cancer treatment using curcumin derivatives

Cancer or a precancerous condition is treated by administering a curcumin derivative to a subject.
Owner:STC UNM

Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer

InactiveUS20020106684A1Low tumor burdenImmunologic function is relatively intactSugar derivativesMicrobiological testing/measurementA lipoproteinNeoplasm
This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.
Owner:ONCOMEDX

Soluble Form of Carbonic Anhydrase IX (s-CA IX), Assays to Detect s-CA IX, CA IX's Coexpression with Her-2/neu/c-erbB-2, and CA IX-Specific Monoclonal Antibodies to Non-Immunodominant Epitopes

Disclosed herein is the discovery of a soluble MN / CA IX (s-CA IX) in body fluids, such as, urine and serum. Said s-CA IX comprises the extracellular domain of CA IX or portions thereof. The Predominant s-CA IX species is the extracellular domain comprising a proteoglycan-like (PG) domain and carbonic anhydrase (CA) domain, and having a molecular weight of about 50 / 54 kilodaltons (kd) upon Western blot. A smaller s-CA IX form of about 20 to about 30 kd comprising the CA domain or parts thereof, not linked to the PG domain, has also been found in body fluids. Diagnostic / prognostic methods for precancer and cancer that detect or detect and quantitate said s-CA IX in body fluids, are described. Also disclosed herein is the coexpression of CA IX and HER-2 / neu / c-erbB-2 that provides parallel, alternative and potentially synergistic diagnostic / prognostic and therapeutic strategies for precancer and cancer. Further disclosed are new MN / CA IX-specific antibodies generated from MN / CA IX-deficient mice, preferably monoclonal antibodies and immunoreactive fragments and engineered variants thereof. Such new MN / CA IX-specific antibodies, fragments and variants are useful diagnostically / prognostically and therapeutically for cancer and precancer. Particularly preferred are the new monoclonal antibodies, fragments and variants that are specific for the non-immunodominant epitopes of MN / CA IX, which antibodies are, among other uses, useful to detect soluble MN / CA IX (s-CA IX) in body fluids, alone but preferably in combination with antibodies specific to the immunodominant epitopes of MN / CA IX, for example, in a sandwich assay.
Owner:BIOMEDICAL RES CENT OF THE SLOVAK ACADEMY OF SCI

Functional Immunohistochemical Cell Cycle Analysis as a Prognostic Indicator for Cancer

The present invention relates to a method of determining the presence of a retinoblastoma protein (Rb)-mediated cancerous or pre-cancerous condition in a sample of fixed cells that involves exposing the sample to an antibody that recognizes phosphorylation of serine on the retinoblastoma protein (pS-Rb), and identifying cells in the sample that are recognized by the anti-O body to pS-Rb, where the recognition of pS-Rb in the sample determines the presence of an Rb-mediated cancerous or pre-cancerous condition. The method also involves identifying the presence of specific cell cycle markers and positive and negative cell cycle regulators to assess the stage of disease progression in a cancer patient having an (Rb)-mediated cancer. The present invention also relates to methods of assessing the efficacy of cancer therapy for an Rb-mediated cancer, determining the mechanism of cell cycle progression in an Rb-mediated cancer, and identifying cells predisposed to developing an Rb-mediated cancerous condition.
Owner:CORNELL RES FOUNDATION INC

Method and kit for detection of early cancer or pre-cancer using blood and body fluids

This invention is related to a method for the detection of early or pre-cancer using DNA isolated from blood and body fluids. This invention provides an improved methylation-based PCR assay, a panel of methylated-based cancer-related gene markers for the detection of general cancer and a panel of demethylation-based tissue- or cell-specific gene markers for discriminating different type of cancer detected from blood samples. This method couples a sequential cancer-related gene marker detection and tissue or cell-specific gene marker assay and is particularly useful as a simultaneous screening test for following type of cancer: lung, breast, ovarian, colon, stomach, prostatic, pancreatic and liver cancer.
Owner:LI WEIWEI +1

Product comprising a nicotine-containing material and an Anti-cancer agent

The present invention provides a composition comprising a nicotine-containing material and an anti-cancer agent usable in the treatment and / or prevention or reduction of the risk of cancer and precancerous conditions as well as for preventing or reducing the risk of cancer recurrence. Furthermore, a composition comprising a nicotine-containing material and an anti-inflammatory agent usable in the treatment and / or prevention or reduction of the risk of inflammation, is provided. The nicotine containing composition can also include both an anti-cancer agent and an anti-inflammatory agent A device for administering the composition of the present invention to subjects can be a cigarette, smoking pipe, smokeless tobacco, electronic cigarette, transdermal patch or the like.
Owner:RIGAS BASIL +1

Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

The invention relates to newly discovered nucleic acid molecules and proteins associated with prostate cancer including pre-malignant conditions. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human prostate cancers are provided.
Owner:MILLENNIUM PHARMA INC

Phospho-ester derivatives and uses thereof

Phospho-ester compounds and pharmaceutical compositions thereof administered by the respiratory and other routes for the prevention and / or treatment of lung and brain cancer and precancerous conditions thereof, for the treatment of pain, for the treatment of skin disorders, for treating and / or preventing inflammation-related diseases, and for the treatment and prevention of cancer.
Owner:MEDICON PHARMA

Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

The invention relates to newly discovered nucleic acid molecules and proteins associated with prostate cancer including pre-malignant conditions. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human prostate cancers are provided.
Owner:MILLENNIUM PHARMA INC

Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions

InactiveUS20080261292A1Assess prognosisPredict prognosisSugar derivativesMicrobiological testing/measurementNeoplasmCirculating RNA
This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.
Owner:ONCOMEDX

Spectral polarizing tomographic dermatoscope

An apparatus for use in examining an object, such as skin, mucosa and cervical tissues for detecting cancer and precancerous conditions therein. In one embodiment, the apparatus includes a gun-shaped housing having a handle portion and a barrel portion. The front end of the barrel portion is open, and a glass cover is mounted therein. LED's are disposed within the handle portion. A manually-operable switch for controlling actuation of the LED's is accessible on the handle portion. An optical fiber is used to transmit light from the LED's through a first polarizer in the barrel portion and then through the glass cover to illuminate a desired object. Reflected light from the object is passed through a second polarizer, which is adjustably mounted in the barrel portion and which is preferably oriented to pass depolarized light emitted from an illuminated object, and is then imaged by optics onto a CCD detector. The detector is coupled to a wireless transmitter that transmits the output from the detector to a remotely located wireless receiver.
Owner:ALFANO ROBERT R +3

Product comprising a nicotine-containing material and an Anti-cancer agent

The invention is directed to a product comprising a nicotine-containing material and an anti-cancer agent. The product is applicable in the treatment and / or prevention of cancer and precancerous conditions as well as for preventing cancer recurrence.
Owner:RIGAS BASIL +1

Anticancer therapy

A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.
Owner:STC UNM

Non-target amplification method for detection of RNA splice-forms in a sample

Provided are methods of isolating RNA from a biological sample, methods and means for determining the presence of particular RNA splice-form variants in a biological sample, methods and means for determining the relative ratio of RNA ratios in a biological sample, and methods and means for predicting the progression of precancerous cervical lesions.
Owner:QIAGEN GAITHERSBURG

Treatment or prevention of cancer and precancerous disorders

The NSAID, sulindac and / or its metabolites and derivatives, in combination with hydrogen peroxide or another oxidizing agent, such as arsenic trioxide that generates reactive oxygen species (ROS), significantly enhances the killing of cancer cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against cancer cells. A skin cream has been developed and used to treat skin cancer and precancerous skin growths that effectively removes the lesions with no effect on surrounding normal skin.
Owner:CHS PHARMA

Surface Receptor Complexes as Biomarkers

The invention is directed to a new class of biomarker in patient samples comprising dimers of cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.
Owner:MONOGRAM BIOSCIENCES

Annexin a2 as immunological target

InactiveUS20110293608A1Prevent intrusionCompound screeningApoptosis detectionAntigenCalcium-dependent phospholipid binding
AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface / membrane AnnexinA2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The cytoplasmic to cell surface translocation of AnnexinA2 expression is critical for pancreatic cancer cell invasion. In addition, phosphorylation of AnnexinA2 at Tyrosine 23 is important for its localization to the cell surface and for the invasion of pancreatic cancer cells. Finally, loss of AnnexinA2 leads to the loss of the Epithelial-Mesenchymal Transition.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

A device and method for cancer detection, diagnosis and treatment guidance using active thermal imaging

The present invention discloses means and methods for detecting irregularities in the cells throughout a healthy tissue. The method generally relates to cancer detection, diagnosis and treatment, and more specifically pertains to detection, diagnosis and treatment guidance of cancerous or precancerous conditions through the use of thermal imaging technology and analysis.
Owner:H T BIOIMAGING LTD

Methods for Detecting Receptor Complexes Comprising PI3K

Abstract of the Disclosure The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.
Owner:MONOGRAM BIOSCIENCES

Compositions and methods for detecting pre-cancerous conditions in cell and tissue samples using 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine

Presented is a method to detect precancerous states in mammalian cell and tissue samples comprising incubating a sample with solubilized 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (TCPP), measuring TCPP fluorescence in the sample, and categorizing the sample as non-cancerous, precancerous or cancerous based on TCPP fluorescence, as correlated with the respective states of the cells. In conjunction with the method a detection, a novel and more efficient method of solubilizing TCPP is presented, as well as a composition comprising TCPP solubilized by this method.
Owner:BIOAFFINITY TECH

Methods for detection of breast cancer

The invention relates to a simple screening test for neoplasia, a precancerous condition, or cancer of the breast. A method is described whereby a breast cancer marker is detected in breast fluid. In a particular embodiment, the method involves treating samples of breast fluids with an aldehyde detecting reagent without any prewashing. The appearance in breast fluids of a marker that is detected by an aldehyde detecting reagent, such as a Schiff s reagent, correlates very well with the disease status of the breast cancer subjects from which the fluids were obtained. Screening test kits are also provided.
Owner:SENTINA BIOTECH

Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions

Disclosed herein are assays and methods for the identification of premalignant lesions, as well as methods of determining the likelihood that such premalignant lesions will progress to lung cancer. Also disclosed are methods and assays that are useful for monitoring the progression of premalignant lesions to lung cancer. The assays and methods disclosed herein provide minimally invasive means of accurately detecting and monitoring the presence or absence of premalignant lesions, thus providing novel insights into the earliest stages of lung cancer and facilitating early detection and early intervention.
Owner:TRUSTEES OF BOSTON UNIV

Hypermethylation biomarkers for detection of cervical cancer

Pap smears and HPV infection tests do not distinguish between lesions that will progress to an invasive carcinoma and those that will not. We aimed to identify epigenetic biomarkers for diagnosis and progression monitoring of premalignant lesions in cervical cancer. Hypermethylated genes were identified as potential biomarkers after validation by MSP, including GGTLA4 and ZNF516. The methylation frequency for these two genes was higher in tumor: GGTLA4 (100%) and ZNF516 (96%); than in normal samples: GGTLA4 (12%) and ZNF516 (16%). The methylation status of GGTLA4 showed a progression in methylation frequency from normal samples to invasive carcinoma. The immunohistochemical expression was lower in tumor for both: GGTLA4 (50.8%) and ZNF516 (66.2%); than in normal samples: GGTLA4 (71.2%) and ZNF516 (88.1%) (p<0.05). In conclusion, we identified methylation biomarkers for the molecular screening and characterization of cervical cancer.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Compositions And Methods Of Treating Head And Neck Cancer

The present invention provides methods related to the treatment of head and neck squamous cell carcinoma (HNSCC) and its associated premalignant lesions. In particular, the invention features methods which may specifically target HNSCC-associated genes and alter gene expression to treat or alleviate a symptom of HNSCC, or its related premalignant lesions. These methods may involve decreasing the function of an HNSCC-associated gene with aberrant gain-of-function; or increasing the function of an HNSCC-associated gene with aberrant loss-of-function.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +6
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products